Skip to content

A clinical trial to assess the safety and efficacy of Col-Red compared with Placebo on reducing cholesterol in hypercholesterolemia patients

A double blinded, randomized, comparative clinical trial to determine the efficacy of Col-Red compared with Placebo on reducing cholesterol in hypercholesterolemia patients - ColRed Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2012/06/002718
Enrollment
30
Registered
2012-06-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I798- Other disorders of arteries, arterioles and capillaries in diseases classified elsewhere

Interventions

Intervention1: ColRed: 15 gms twice a day in luke warm water or milk for 2 months. Intervention2: ColRed: 30 gms once a day in luke warm water or milk for 2 months. Control Intervention1: Placebo: 1

Sponsors

British Biologicals
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: A total of 30 Subjects aged between 18-65 years with known but untreated moderate hypercholesterolemia. Subjects diagnosed with total cholesterol equal to or above 200 mg/dl and who have LDL-cholesterol levels equal to or above 130 mg/dl Subjects who give their consent to participate after being informed of the study objectives

Exclusion criteria

Exclusion criteria: Severe disease necessitating pharmacological intervention Hepatic disease, gastrointestinal complaints and ulcers, thyroid dysfunction or any kidney disease; Personal history of cardiovascular illness. Uncontrolled diabetes and uncontrolled hypertension in terms of the WHO criteria (140/90 mmHg) Known food allergy. Significant chronic organic or psychiatric disease Not obtaining informed consent Pregnant or lactating subjects.

Design outcomes

Primary

MeasureTime frame
â?¢ The difference between treatment groups in the percent change from baseline to the end of treatment in LDL-CholesterolTimepoint: At week 2, week 4 and and week 8(study end).

Secondary

MeasureTime frame
Change in other lipid levels (total cholesterol, HDL-cholesterol and triglycerides) Incidence of adverse events â?¢ Quality of life assessment of the subjects â?¢ Feedback with regard to product taste and consumption habits Timepoint: At week 2, week 4 and and week 8(study end).

Countries

India

Contacts

Public ContactDr Manjunath

ICBio Clinical Research Pvt. Ltd.

vikram.baburao@icbiocro.com919900111993

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026